Prevalence of High Blood Pressure and its Relationship with Body Weight Factors among Inpatients with Schizophrenia in Taiwan

Lan, Yu-Li; Chen, Tzy-Ling

doi:10.1016/j.anr.2012.02.003

Cited by 10 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is reflected in our logistic regression analysis because factors in our sample could account for low variance. Our findings on the prevalence of HTN are lower than those of a study done in Taiwan, 15 which had mostly inpatients who were more severely ill. But obesity and SGA use are similar to the findings of the Taiwan study.…”

Section: Discussioncontrasting

confidence: 95%

“…Newer studies done after the introduction of SGAs have found HTN to be more prevalent among inpatients with schizophrenia than the general population in Taiwan, and HTN was significantly associated with a higher BMI. 15 HTN without any other cardiometabolic comorbidity is found to have more accelerated cardiac effects than the age-matched general population. 16 The prevalence of cardiovascular diseases and their risk factors has increased worldwide, and similarly for persons with schizophrenia.…”

Section: Introductionmentioning

confidence: 89%

“…4−10 There is evidence that the prevalence of HTN in persons with schizophrenia might be increasing compared to the pre-SGA era. 1,15 This might be due to metabolic risk mediated by an increased body mass index due to these SGA medications and health-related lifestyle factors. Therefore, we aimed to study the prevalence of HTN, biophysical parameters, and health-related lifestyle behaviors (physical activity and substance use) in persons with schizophrenia attending outpatient services, with our hypothesis being that the prevalence of HTN will be higher than that of the general population.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Study of Hypertension and Related Biophysical and Health-related Lifestyle Behaviors in Patients Suffering from Schizophrenia

Basera

Suri

Singh

2023

Annals of Neurosciences

View full text Add to dashboard Cite

Background Schizophrenia is a life-shortening disease. The standardized mortality ratio has been higher than that of the general population, and it has doubled what it was 3-4 decades ago. This rise is mostly attributed to the increased cardiovascular risk associated with high second-generation antipsychotic (SGA) use. Evidence from the first-generation antipsychotic (FGA) era shows a lower prevalence of hypertension (HTN) but data regarding SGAs is scarce. Purpose The purpose of the study was to assess the prevalence of HTN and related factors using standardized methodology in patients with schizophrenia on treatment with SGAs. Methods A cross-sectional study through convenient sampling was done. Blood pressure, anthropometry, physical activity, and health-related lifestyle factors were assessed using the standard World Health Organization (WHO) methodology of cardiovascular survey methods and the Global Physical Activity Questionnaire (GPAQ) version 2. The prevalence of HTN, obesity, inadequate physical activity, and other demographic and clinical correlates like antipsychotic use, duration of illness, and family history of non-communicable diseases (NCDs) were studied. Results The prevalence of HTN is 20.50%, and it increases with age. SGAs with the use of a single agent are the most common. In total, 45.50% of persons with schizophrenia have a positive family history of a NCD; 22.00% and 07.50% are current tobacco and alcohol users, respectively; and 70% have abdominal obesity, and 54% have generalized obesity. Waist circumference, obesity, and family history of NCDs are significant correlates of HTN. A family history of NCDs is the most significant predictor. Conclusion The prevalence of HTN is lower than that of the general population despite the high prevalence of SGA use, obesity, and inadequate physical activity.

show abstract

Section: Discussioncontrasting

confidence: 95%

Section: Introductionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Study of Hypertension and Related Biophysical and Health-related Lifestyle Behaviors in Patients Suffering from Schizophrenia

Basera

Suri

Singh

2023

Annals of Neurosciences

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is also reported that the increase in BP could also be partly linked to increases in body weight and BMI in psychotic patients. 41 The increase in BP by AAPs is mediated via the dopaminergic system through D1, D3, and D4 receptors which are hypothesized to interact with the renin–angiotensin–aldosterone system. Furthermore, it is suggested that dopaminergic receptors, D2 and D5, when activated, also inhibit the production of norepinephrine consequently leading to the increase in BP.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Side Effects of Olanzapine in Patients With Psychotic Disorders in Oman: A Retrospective Cohort Study

et al. 2022

View full text Add to dashboard Cite

We evaluated the impact of olanzapine on metabolic changes in patients with psychotic disorders. This was a retrospective cohort study involving patients prescribed olanzapine and attending Sultan Qaboos University Hospital (Muscat, Oman). Patients were followed up retrospectively from March 2006 until April 2021. Cardiovascular treatment targets were evaluated as per the 2019 European Society of Cardiology guidelines. We enrolled 253 patients (mean age: 40±17 years). Olanzapine monotherapy was associated with increased body weight (+8 kg; 95% confidence interval (CI): 6–9; P < .001), body mass index (+3 kg/m2; 95% CI: 2–4; P < .001), total cholesterol (+.4 mmol/L; 95% CI: .3–.5; P < .001), low-density lipoprotein cholesterol (LDL-C) (+.3 mmol/L; 95% CI: .1–.4; P < .001), fasting triglycerides (+.2 mmol/L; 95% CI: .1–.3; P<.001), fasting glucose (+.6 mmol/L; 95% CI: .4–.7; P< .001), HbA1c (+.3%; 95% CI: .2–.4; P < .001), systolic blood pressure (BP) (+9 mmHg; 95% CI: 6–12; P < .001) and diastolic BP (+4 mmHg; 95% CI: 2–6; P < .001) levels. Cardiovascular therapeutic goals were attained in 38% (n = 97), 61% (n = 154), 71% (n = 180), and 59% (n = 150) for LDL-C, non–high-density lipoprotein cholesterol, triglycerides, and BP, respectively. Olanzapine was associated with adverse metabolic changes. Therefore, many patients were not at their target cardiovascular treatment goals.

show abstract

“…[1] The excess mortality and morbidity in schizophrenia is largely attributed to comorbidities such as diabetes mellitus (DM), cardiovascular diseases (CVD), hypertension (HTN), obesity, and dyslipidemia. [123]…”

Section: Introductionmentioning

confidence: 99%

Prevalence and predictors of metabolic syndrome in schizophrenia patients from Assam

Das¹,

Bora

Baruah³

et al. 2017

Indian J Psychiatry

View full text Add to dashboard Cite

Background:Metabolic abnormalities contribute enormously to morbidity and mortality in schizophrenia.Objectives:Our objectives were to determine the (i) prevalence of metabolic syndrome (MS); and (ii) predictors for MS in schizophrenia patients from Assam.Materials and Methods:Seventy-five schizophrenia patients were evaluated for MS. Risk factors were assessed by odds ratios (ORs) with 95% confidence intervals (CIs).Results:Fifty-nine patients (78.7%) had a metabolic abnormality. Twenty-two patients (29.3%, 95% CI: 19.9%–40.8%) fulfilled the criteria for MS. Female gender (adjusted OR = 7.8, 95% CI: 1.7–36.4), smoking (adjusted OR = 7.9, 95% CI: 1.7–35.8), family history of chronic lifestyle disease (adjusted OR = 4.4, 95% CI: 1.3–15.2), and atypical antipsychotic use (adjusted OR = 4.3, 95% CI: 1.1–16.9) significantly predicted MS.Conclusion:Metabolic abnormalities exist widely in schizophrenics from Assam. Females, smokers, and those with family history of chronic diseases and using atypical antipsychotics are at greater risk.

show abstract

Prevalence of High Blood Pressure and its Relationship with Body Weight Factors among Inpatients with Schizophrenia in Taiwan

Cited by 10 publications

References 30 publications

A Study of Hypertension and Related Biophysical and Health-related Lifestyle Behaviors in Patients Suffering from Schizophrenia

A Study of Hypertension and Related Biophysical and Health-related Lifestyle Behaviors in Patients Suffering from Schizophrenia

Metabolic Side Effects of Olanzapine in Patients With Psychotic Disorders in Oman: A Retrospective Cohort Study

Prevalence and predictors of metabolic syndrome in schizophrenia patients from Assam

Contact Info

Product

Resources

About